UNSPSC 51383507: Indometacin or indomethacin

This classification denotes an indole compound and cyclooxygenase inhibitor with the molecular formula C19H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XXE1CET956, chemically known as 1h-indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- (9ci) but generally known as indometacin, which bears US NIH Compound Identifier 3715. European Medicines Agency schedules Indometacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08180MIG.

UNSPSC 51383507 Indometacin or indomethacin is a Commodity code that in practice captures state and local procurement of pharmaceutical products, including generic multi-source pharmaceuticals, over-the-counter medications, and specialty drugs like naloxone. The recent solicitations under this code show that state and local bodies purchase finished pharmaceutical inventory for community health programs, state health agency benefit plans, and authorized distribution through pharmacy benefit networks. Issuing bodies include county health departments (such as Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The purchasing mix spans direct county procurement of discrete drug quantities for quarterly delivery, state-level market research into direct-to-manufacturer contracting models, and cooperative contracting vehicles that aggregate demand across multiple states and local jurisdictions.

Recent activity clusters in Florida, Texas, and Minnesota-led cooperative procurement spanning multiple states including Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding with a response deadline of July 26, 2023 (note: posted date of June 30, 2026 with a due date of July 26, 2023 reflects a data inconsistency in the source), with quarterly deliveries to the county's community health building and all shipping costs to be included in vendor proposals. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmaceutical prescription programs as a preliminary phase before issuing a formal request for proposal. The Minnesota Department of Administration, administering MMCAP, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) with contract effectiveness targeted for July 1, 2026. Vendors must hold pharmaceutical manufacturing compliance certifications including cGMP and DSCSA and maintain minimum insurance including $5 million commercial general liability.